AI in Healthcare Venture Capital: Where the Durable Moats Are Forming

Healthcare AI has become one of the fastest-growing areas in venture capital, but the investment question is changing. It is no longer enough to ask whether a company uses artificial intelligence or has access to a powerful model. Models are improving quickly, inference costs are falling, and capabilities that looked extraordinary two years ago are increasingly available through commercial APIs and open-source systems.

Presented By Our Partners

The more useful question is: What remains defensible when the underlying model becomes cheaper, better, and more widely available?

In healthcare, the answer is rarely a single algorithm. Durable value forms around the system surrounding the model: the workflow it owns, the data it earns permission to learn from, the evidence it produces, the regulatory obligations it can manage, the distribution it controls, and the economic or clinical outcome it can prove.

That distinction matters because capital is moving into healthcare AI at extraordinary speed. Bessemer Venture Partners estimated that AI companies captured 55% of health-tech funding in 2025, up from 37% in 2024 and 29% in 2022. It also estimated that healthcare AI startups received 22 cents of every venture dollar invested in AI companies overall. Some healthcare AI businesses have reached $100 million or even $200 million in annual recurring revenue in fewer than five years—far faster than traditional healthcare-software companies historically reached the same scale.

Those numbers establish demand. They do not establish durability.

This article extends HealthcareDiscovery.ai’s broader Healthcare Venture Capital in 2026 analysis by examining where the real moats are forming—and where apparent differentiation may disappear.

Why the Model Alone Is Usually Not the Moat

A foundation model can be technically impressive and strategically weak at the same time. If several companies can access comparable reasoning, language, image, or multimodal capabilities, then model access becomes an input rather than a defensible business.

Healthcare intensifies that problem. A model must operate inside fragmented systems, inconsistent data, specialized clinical language, privacy constraints, long procurement cycles, and workflows where mistakes can create financial or patient harm. General intelligence does not automatically translate into reliable healthcare execution.

An investor should therefore separate three layers:

• Model capability: Can the system perform the task in a controlled evaluation?
• Product capability: Can people use it safely and consistently inside a real workflow?
• Business durability: Can the company retain customers, improve over time, and defend its position as models and competitors advance?

The first layer may be copied quickly. The second and third are where healthcare-specific value accumulates.

The Pilot-to-Production Gap Is an Investment Signal

The Healthcare AI Adoption Index, produced by Bessemer with AWS and Bain & Company from a survey of more than 400 healthcare leaders, found intense experimentation but limited production deployment.

Only 30% of completed generative-AI proofs of concept reached production. Large providers performed better, moving 46% of their completed pilots into production, but the broader conversion rate exposes the real difficulty of healthcare AI.

The main barriers were not a lack of enthusiasm or budget. Buyers cited security concerns, limited in-house AI expertise, costly integrations, and difficulty preparing AI-ready data. Sixty percent of respondents said AI budgets were growing faster than general IT budgets, and 70% of AI use-case decisions were controlled by C-suite leaders.

This creates a powerful diligence filter. A company that survives the transition from demonstration to production has solved problems that a benchmark does not capture:

• information-security review;
• data access and normalization;
• integration with systems of record;
• user training and workflow redesign;
• governance and escalation;
• performance monitoring;
• and proof that the result is worth the disruption.

In other words, production deployment is not merely a sales milestone. It is evidence that part of the moat exists.

Moat One: Ownership of a High-Value Workflow

The strongest healthcare AI companies do not sit beside the work. They become part of how the work is completed.

Ambient clinical documentation is an instructive example. The category gained traction because it addresses an obvious pain point: clinicians spend enormous time documenting care. But transcription by itself can become commoditized. The more durable platform may connect the encounter to coding, orders, patient instructions, quality reporting, follow-up, and revenue-cycle processes.

The same logic applies across healthcare:

• an imaging model becomes more valuable when it helps prioritize work, document findings, route urgent cases, and close follow-up;
• a prior-authorization tool becomes more valuable when it assembles evidence, submits the request, tracks the decision, manages appeals, and measures time to completed care;
• a clinical-trial tool becomes more valuable when it identifies patients, supports site workflow, manages documentation, and improves enrollment;
• a revenue-cycle product becomes more valuable when it moves from identifying missed revenue to resolving the underlying claim workflow.

Workflow ownership creates switching costs because the customer is no longer buying a prediction. It is relying on the company to complete an operational process.

The key diligence question is: If the model disappeared tomorrow, what customer process, integration, or operating capability would still make the company difficult to replace?

Moat Two: Proprietary, Permissioned Learning Data

Healthcare data can create a moat, but only when the company has the legal right, technical ability, and customer trust required to use it responsibly.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Large datasets are not automatically valuable. Claims, notes, images, laboratory results, device readings, outcomes, and operational events all contain different biases and missing context. Data collected in one institution may not generalize to another. Historical records can encode inequities, inconsistent documentation, and changing clinical practice.

The best data advantage is usually generated through product use. A system operates inside a workflow, observes what happened, receives corrected outputs or outcome feedback, and improves. This creates a learning loop competitors cannot purchase as a static dataset.

Investors should ask:

1. What unique data does the product generate or organize?
2. Does the company have clear permission to use it for improvement?
3. Is the data linked to meaningful outcomes rather than proxy labels?
4. Does usage improve the product for the same customer, across customers, or both?
5. Can the advantage survive privacy restrictions, customer termination, and model-vendor changes?

A proprietary dataset can be a moat. A pile of inaccessible or legally ambiguous records is a liability.

Moat Three: Evidence That Matches the Risk

Healthcare AI companies often cite accuracy, sensitivity, specificity, time saved, or user satisfaction. Those measures can be useful, but they answer different questions.

Investors should distinguish:

• technical evidence: the model performs a defined task;
• workflow evidence: people use it successfully in practice;
• clinical evidence: its use changes a meaningful health or care outcome;
• economic evidence: it saves money, creates revenue, improves capacity, or reduces risk;
• generalizability evidence: the result holds across populations and settings;
• longitudinal evidence: performance remains reliable as data and practice change.

The appropriate burden depends on the claim. An administrative drafting tool does not require the same evidence as software that influences diagnosis or treatment. But every company needs evidence proportionate to the consequence of being wrong.

Evidence creates a moat because it takes time, customer access, operational discipline, and credibility to produce. It also reduces procurement friction. In the adoption survey, healthcare executives emphasized attributable return on investment and proven track records. A company with peer references and replicated outcomes competes differently from a company selling possibility.

Moat Four: Regulatory and Lifecycle Capability

For regulated clinical AI, clearance or approval can create an entry barrier—but the deeper moat is the capability to manage the full product lifecycle.

The FDA emphasizes that AI-enabled medical devices require careful management throughout development, deployment, use, and maintenance. Its guidance work addresses good machine-learning practice, transparency, predetermined change-control plans, and lifecycle management.

That matters because AI products can change. Data distributions shift. Clinical practice evolves. New subgroups expose performance gaps. A model vendor updates an underlying system. Regulators and customers increasingly expect manufacturers to explain intended use, validation, monitoring, changes, and risk controls.

A durable regulatory capability therefore includes:

• a clearly defined intended use;
• quality-management systems;
• representative validation data;
• human-factors and workflow testing;
• change-control procedures;
• post-market monitoring;
• transparency about limitations;
• and the ability to investigate and correct performance problems.

Regulatory authorization is a milestone. The organizational ability to keep an AI medical product safe, current, and trusted is the moat.

Moat Five: Distribution and Trusted Access

Healthcare distribution is slow to build and difficult to fake. Health systems, physicians, payers, pharmaceutical companies, laboratories, and patients do not adopt consequential technology solely because a product demonstration is impressive.

They adopt through trusted relationships, integrations, procurement pathways, clinical champions, reference customers, and evidence that another organization like theirs succeeded.

The adoption survey showed both the opportunity and the difficulty for startups. Fewer than 15% of AI projects were being developed and procured from vertical AI startups, while buyers also relied on internal teams, large technology companies, cloud providers, and incumbent healthcare IT vendors. Only 32% of surveyed executives believed startup products were superior to solutions from large incumbents. Yet 48% preferred working with innovative startups, and 64% were open to co-development with early-stage partners.

That is not a closed market. It is a market demanding proof and partnership.

The most defensible startups often enter through one urgent use case, co-build with credible customers, and then expand. Distribution becomes stronger as the company collects references, integrates more deeply, and serves adjacent stakeholders.

Moat Six: Attributable Economic Value

AI can create value through labor savings, increased capacity, recovered revenue, reduced leakage, faster research, better patient retention, or improved outcomes. But investors should be suspicious of value claims that cannot be attributed.

The strongest businesses can show a before-and-after result:

• minutes of documentation reduced per clinician;
• claims coded or recovered;
• authorization turnaround reduced;
• appointments completed;
• trial enrollment accelerated;
• readmissions or complications avoided;
• or research cycles compressed.

Economic proof matters because healthcare budgets are fragmented. The department paying for a product may not receive the savings. A tool can generate system-wide value and still fail if the buyer cannot capture it.

An investable company understands who pays, who benefits, who bears implementation cost, and how value appears in that buyer’s budget. This is why revenue-cycle and administrative AI have attracted early adoption: the return is often measurable within months rather than years.

Moat Seven: Expansion Into a Platform

A healthcare AI company becomes substantially more valuable when its first workflow creates a credible path into adjacent workflows.

Bessemer describes a shift from workflow tools toward mission-critical infrastructure and notes that strategic buyers are acquiring AI capabilities to expand point solutions into broader platforms. Global health-tech M&A reached 400 deals in 2025, up from 350 in 2024, with AI increasingly tied to revenue growth and margin improvement.

Platform expansion should not mean adding unrelated features. The strongest expansion follows the data and workflow already owned.

An ambient documentation company may expand into coding and clinical intelligence. A revenue-cycle company may expand from one claim stage across the full payment workflow. A research platform may connect data generation, experiment design, analysis, and therapeutic development.

The test is whether every additional module strengthens the existing system. If expansion creates more data, deeper integration, better outcomes, and higher switching costs, the moat compounds. If it merely increases the slide count, it does not.

Where Healthcare AI Moats Are Weakest

Several patterns deserve caution:

• a thin interface around a third-party model with no proprietary workflow;
• a product whose advantage disappears when the system of record adds the same feature;
• impressive retrospective performance without prospective deployment;
• data rights that are unclear or dependent on one customer;
• revenue based on pilots that never convert to enterprise rollout;
• regulatory claims that exceed the product’s actual authorization;
• savings that benefit someone other than the buyer;
• and valuation based primarily on category excitement rather than retention and outcomes.

None of these automatically makes a company uninvestable. They change the price, evidence burden, and financing strategy.

A Practical Healthcare AI Investment Scorecard

Before treating a healthcare AI company as defensible, investors should be able to answer:

1. Workflow: What complete job does the company own?
2. Data: What learning advantage grows through use?
3. Evidence: What has been proven technically, operationally, clinically, and economically?
4. Regulation: What obligations apply, and can the company manage the lifecycle?
5. Distribution: Why can this company reach and retain buyers?
6. Economics: Who captures the value, and how quickly is it visible?
7. Expansion: Does the first product create a credible platform path?
8. Commoditization: What survives if model quality improves and inference costs fall by another order of magnitude?

The last question is especially important. A strong healthcare AI company should benefit from better models without losing its reason to exist.

The Investment Thesis for 2026

Healthcare AI is not one market. It includes administrative automation, clinical decision support, diagnostics, research infrastructure, drug development, care navigation, patient engagement, and new care-delivery companies. The evidence and economics differ across each category.

But the common investment thesis is becoming clearer.

The durable winners will convert model capability into an operating system for a valuable healthcare workflow. They will earn proprietary data through use, build evidence proportional to risk, manage regulation over time, reach customers through trusted distribution, prove attributable value, and expand without losing focus.

The underlying model may change many times. The healthcare system surrounding it is what compounds.

HealthcareDiscovery.ai will continue tracking that system across this healthcare venture-capital cluster—from autonomous laboratories and generative biology to care delivery, longevity, devices, and the discovery-to-delivery investment map.

For readers exploring the affiliated investment platform, Healthcare Venture Capital Fund is developing a healthcare-focused, deal-by-deal investment model. Healthcare Venture Capital Fund and HealthcareDiscovery.ai are affiliated projects; this reference is provided for transparency and information, not as an offer, solicitation, or recommendation to invest.

Sources and Further Reading

• Bessemer Venture Partners, State of Health AI 2026.
• Bessemer Venture Partners, AWS, and Bain & Company, The Healthcare AI Adoption Index.
• U.S. Food and Drug Administration, Artificial Intelligence in Software as a Medical Device.
• FDA, Artificial Intelligence-Enabled Medical Devices.
• HealthcareDiscovery.ai, Healthcare Venture Capital in 2026.

This article is for informational and educational purposes only. It does not constitute investment, legal, tax, or medical advice, an offer to sell securities, or a solicitation to purchase any investment.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.